Compare LUNG & MRLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | MRLN |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.1M | 86.8M |
| IPO Year | 2020 | 2024 |
| Metric | LUNG | MRLN |
|---|---|---|
| Price | $2.53 | $1.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $3.70 | ★ $7.92 |
| AVG Volume (30 Days) | 279.2K | ★ 2.6M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,497,000.00 | N/A |
| Revenue This Year | $0.06 | $9.23 |
| Revenue Next Year | $8.58 | $153.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $1.13 | $0.82 |
| 52 Week High | $2.66 | $17.00 |
| Indicator | LUNG | MRLN |
|---|---|---|
| Relative Strength Index (RSI) | 77.09 | 35.97 |
| Support Level | $1.20 | N/A |
| Resistance Level | N/A | $3.45 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 85.71 | 51.75 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Merlin Inc develops software that fulfills the functions of a human pilot in self-flying aircraft to enable both reduced crew and unmanned flight. This technology is designed to be scalable and adaptable across different aircraft types for a growing range of aircraft platforms. The company's aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, through hundreds of autonomous flights from test facilities across the globe. It operates as a single operating and reportable segment.